INT201130

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.63
First Reported 2005
Last Reported 2011
Negated 2
Speculated 0
Reported most in Body
Documents 31
Total Number 33
Disease Relevance 25.45
Pain Relevance 5.12

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (AES)
Anatomy Link Frequency
hip 2
blood 1
upper respiratory tract 1
chest 1
respiratory 1
AES (Homo sapiens)
Pain Link Frequency Relevance Heat
headache 70 99.76 Very High Very High Very High
Sumatriptan 47 99.60 Very High Very High Very High
Pain 141 99.02 Very High Very High Very High
cva 70 97.72 Very High Very High Very High
abdominal pain 7 95.80 Very High Very High Very High
pruritus 10 95.68 Very High Very High Very High
Angina 8 95.60 Very High Very High Very High
dexamethasone 92 94.56 High High
rheumatoid arthritis 73 93.88 High High
Infliximab 68 92.84 High High
Disease Link Frequency Relevance Heat
Infection 182 100.00 Very High Very High Very High
Toxicity 57 100.00 Very High Very High Very High
Death 40 100.00 Very High Very High Very High
Dyspnea 16 100.00 Very High Very High Very High
Neutropenia 14 100.00 Very High Very High Very High
Thrombocytopenia 9 100.00 Very High Very High Very High
Respiratory Distress 3 100.00 Very High Very High Very High
Headache 117 99.76 Very High Very High Very High
Vomiting 113 99.76 Very High Very High Very High
Fever 22 99.58 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The other grade 1 or grade 2 AEs related to infusions included flushing (five patients), hypotension (three patients), headache (three patients), and chest pain, angioedema and bronchospasm (one case each).
Localization (related) of AEs in chest associated with pressure and volume under development, angina, pressure volume 2 under development, bronchospasm, headache and increased venous pressure under development
1) Confidence 0.63 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC2833973 Disease Relevance 1.94 Pain Relevance 0.30
In a randomized, single-dose, double-blind, parallel-group, placebo-controlled, multicenter clinical study (Dowson et al 2002) that compared almotriptan, 12.5 mg and 25 mg, with sumatriptan 100 mg, a very low rate of AEs was found for both the study drugs.
Localization (rate) of AEs associated with sumatriptan
2) Confidence 0.61 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2656322 Disease Relevance 0.73 Pain Relevance 0.64
For example, bone pain, nausea, fatigue, and fever are the most common AEs reported in bisphosphonate-treated patients.27 Acute flu-like symptoms, which commonly occur after initial exposure to bisphosphonate agents, are related to activation of ??
Localization (reported) of AEs associated with pain, vomiting, fatigue and fever
3) Confidence 0.59 Published 2010 Journal Patient Prefer Adherence Section Body Doc Link PMC3003608 Disease Relevance 0.64 Pain Relevance 0.20
All AEs were generic and not related to the material.
Neg (not) Localization (related) of AEs
4) Confidence 0.59 Published 2010 Journal Int Urogynecol J Section Body Doc Link PMC2977052 Disease Relevance 0.50 Pain Relevance 0.08
The most commonly reported AEs were GI signs and symptoms (Table 2).
Localization (reported) of AEs
5) Confidence 0.48 Published 2010 Journal Diabetic Medicine Section Body Doc Link PMC2948428 Disease Relevance 1.23 Pain Relevance 0.29
Overall, the number of subjects who reported GI AEs decreased over time and did not increase following titration to the higher doses (30 or 40 mg).
Localization (reported) of AEs
6) Confidence 0.48 Published 2010 Journal Diabetic Medicine Section Body Doc Link PMC2948428 Disease Relevance 1.07 Pain Relevance 0.20
We also found that AEs as well as discontinuations for AEs most often occurred during the first 26 weeks of treatment.
Localization (occurred) of AEs
7) Confidence 0.48 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2911915 Disease Relevance 0.92 Pain Relevance 0.55
The most frequently reported AEs were low hemoglobin count (<8 g/dL; n=161, 13.3%), low neutrophil count (<1.0x109/L associated with fever of ?
Localization (reported) of AEs in neutrophil associated with fever
8) Confidence 0.47 Published 2011 Journal Journal of Cancer Section Body Doc Link PMC3020361 Disease Relevance 0.92 Pain Relevance 0
The effect of prognostic factors on an occurrence of any selected adverse events (AEs; neutropenia, thrombocytopenia, reduced haemoglobin, infection requiring hospitalisation or intravenous antibiotics, respiratory distress syndrome, dyspnea, death, or life-threatening toxicity) and methylation of p16 and RASSF1A were assessed.


Localization (methylation) of AEs in respiratory associated with neutropenia, toxicity, thrombocytopenia, dyspnea, respiratory distress, death and infection
9) Confidence 0.47 Published 2011 Journal Journal of Cancer Section Body Doc Link PMC3020361 Disease Relevance 1.12 Pain Relevance 0
We found an association with higher age and the appearance of AEs overall.
Localization (appearance) of AEs
10) Confidence 0.45 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2911915 Disease Relevance 0.97 Pain Relevance 0.21
Although an association towards a greater rate of AEs was observed in patients who continued to smoke during therapy, this was not statistically significant.
Localization (rate) of AEs
11) Confidence 0.44 Published 2011 Journal Journal of Cancer Section Body Doc Link PMC3020361 Disease Relevance 1.23 Pain Relevance 0
The most frequently reported unsolicited AEs in both groups were infections such as upper respiratory tract infections, nasopharyngitis and rhinitis, and dizziness.
Localization (reported) of AEs in upper respiratory tract associated with common cold, rhinitis, dizziness, nasopharyngitis and infection
12) Confidence 0.34 Published 2010 Journal Journal of Korean Medical Science Section Body Doc Link PMC2908791 Disease Relevance 1.67 Pain Relevance 0.11
Potential prolactin-related AEs were reported in ?
Localization (reported) of AEs
13) Confidence 0.33 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2656329 Disease Relevance 0.47 Pain Relevance 0
In the Marder et al study, potential prolactin-related AEs were experienced by 4 patients (0.9%), including 3 men (2 patients on placebo, 1 patient on paliperidone ER 12 mg), and 1 woman (on paliperidone ER 12 mg), but did not result in study discontinuation.
Localization (potential) of AEs
14) Confidence 0.33 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2656329 Disease Relevance 0.75 Pain Relevance 0
Safety measures included frequency and severity of AEs, serious AEs (SAEs); discontinuation due to AEs, abnormal laboratory results, physical examination, vital signs, body mass index (BMI), waist/hip measurement and metabolic syndrome parameters.


Localization (serious) of AEs in hip associated with obesity and metabolic syndrome
15) Confidence 0.32 Published 2010 Journal Ann Gen Psychiatry Section Body Doc Link PMC2949853 Disease Relevance 0.28 Pain Relevance 0
The most frequently reported AEs (occurring in ?
Localization (occurring) of AEs
16) Confidence 0.32 Published 2010 Journal Ann Gen Psychiatry Section Body Doc Link PMC2949853 Disease Relevance 1.11 Pain Relevance 0.17
The most frequently reported AEs (occurring in ?
Localization (reported) of AEs
17) Confidence 0.32 Published 2010 Journal Ann Gen Psychiatry Section Body Doc Link PMC2949853 Disease Relevance 1.10 Pain Relevance 0.17
Safety measures included frequency and severity of AEs, serious AEs (SAEs); discontinuation due to AEs, abnormal laboratory results, physical examination, vital signs, body mass index (BMI), waist/hip measurement and metabolic syndrome parameters.


Localization (serious) of AEs in hip associated with obesity and metabolic syndrome
18) Confidence 0.32 Published 2010 Journal Ann Gen Psychiatry Section Body Doc Link PMC2949853 Disease Relevance 0.29 Pain Relevance 0
Response rates and common AEs are reported in Table 4.
Localization (reported) of AEs
19) Confidence 0.26 Published 2009 Journal Journal of Oncology Section Body Doc Link PMC2668926 Disease Relevance 1.02 Pain Relevance 0.10
AEs were
Localization (were) of AEs
20) Confidence 0.26 Published 2009 Journal Journal of Oncology Section Body Doc Link PMC2668926 Disease Relevance 0.62 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox